Kynos Therapeutics Emerges from Stealth with £9 Million Financing and Phase 1-ready KMO Inhibitor |
| April 07, 2022 | April 2022 Bond Updates |
|
Spin-out from the University of Edinburgh commercialising a decade of drug discovery research on kynurenine 3-monooxygenase (KMO), a pivotal enzyme in the kynurenine pathway of tryptophan metabolism Kynos programmes are focused on three key areas: in critical illness post-surgery; in... |
| View more at: https://www.prnewswire.com:443/news-releases/kynos-therapeutics-emerges-from-stealth-with-9-million-financing-and-phase-1-ready-kmo-inhibitor-301519097.html |
| Related News |